CHICAGO--(BUSINESS WIRE)--Marcus & Boxerman announces that it is investigating claims of potential misrepresentations by Amicus Therapeutics, Inc. (“Amicus” or the “Company”) (Nasdaq: FOLD). The investigation will focus on whether the Company and its officers violated securities laws by issuing misleading statements and/or failing to disclose material information to investors.
To participate in this class action lawsuit, please contact Michael Boxerman, Esquire, of Marcus & Boxerman, at 312-216-2730, or via email at mboxerman@marcusboxerman.com.
On October 2, 2015, Amicus announced that after meeting with FDA officials, the Company does not anticipate being able to submit a new drug application (NDA) for migalastat, the company's Fabry disease treatment, by the end of the year.
No class has been certified in the above action. Until a class is certified, you are not considered represented by an attorney. You may also choose to do nothing and be an absent class member.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.